Skip Navigation

JNCI Journal of the National Cancer Institute 2003 95(2):102-104; doi:10.1093/jnci/95.2.102
© 2003 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Schultz, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schultz, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 95, No. 2, 102-104, January 15, 2003
© 2003 Oxford University Press

NEWS

Success of Vaccine Offers Promise of Cervical Cancer Prevention

James Schultz

The first 10% of the full text of this article appears below.

Although researchers are not yet ready to declare victory over cervical cancer, one crucial battle may have been won. In late November, pharmaceutical maker Merck & Company Inc. announced that, 2 years into a planned 4-year proof-of-principle study, the company’s investigational vaccine against human papillomavirus type 16 (HPV16) is working exactly as designers had hoped: It eliminated the risk of infection with HPV16 in 100% of women who were not previously infected.

The investigation involved 2,392 American women ranging in age from 16 to 23 who were randomly assigned . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?